Akero returns with more MASH data to back PhIII drug, touts fibrosis response rate

Akero Ther­a­peu­tics is back with more da­ta for its FGF21 ana­log in meta­bol­ic dys­func­tion-as­so­ci­at­ed steato­hep­ati­tis (MASH), a dis­ease space that’s been plagued by a string of fail­ures but has re­cent­ly seen a re­ju­ve­na­tion of in­ter­est due to GLP-1 da­ta and the po­ten­tial ap­proval of a treat­ment as ear­ly as this month.

The drug can­di­date, efrux­ifer­min, is al­ready in a Phase III pro­gram re­cruit­ing a va­ri­ety of MASH pa­tients. In re­sponse to Mon­day’s da­ta, Akero’s stock $AKRO jumped by as much as 72% to $48 pre­mar­ket, and then set­tled at around $32.86 (an 18% jump) once the mar­ket opened.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.